Sichuan Qingmu Pharmaceutical Co., Ltd.

Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).

Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of veterinary APIs.

Focus on business in regulated markets, Qingmu was inspected and approved by US FDA, Korea MFDS, and China NMPA, and also approved by customer audit from China, Europe, USA and Japan, etc.

Please contact us for more discussion:
Sichuan Qingmu Pharmaceutical Co., Ltd.
International Sales Department
Tel: 0086-28-87827187
E-mail: sales@eastonpharma.cn
www.qingmupharm.com

Basic Information
Company Name:	Sichuan Qingmu Pharmaceutical Co., Ltd.
Business Type:	Manufacturer
Product/Services:	API,CDMO,Afoxolaner,Firocoxib, Fluralaner,Maropitant Citrate,Maropitant Base,Oclacitinib Maleate,Sarolaner,Lotilaner,Robenacoxib,
Brands:	Qingmu
Number of Employees:	400 to 449
Company Website URL:	TradeNews.html
Ownership & Capital
Year Established:	2011
Legal Form:	Corporation/Limited Liability Company
Registration No.:	91511402572797385X
Issuing Authority:	Administration for Market Regulation
Date of Issue:	March 16, 2023
Date of Expiry:	N/A
Registered Capital:	Meishan City, Sichuan Province